This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
September is National Atrial Fibrillation (AFib) Awareness Month, a time dedicated to raising awareness about one of the most common yet often misunderstood heart conditions. Physicians have a crucial role in recognizing, diagnosing, and managing AFib to prevent its potentially life-threatening complications.
September is National Atrial Fibrillation (AFib) Awareness Month, a time dedicated to raising awareness about one of the most common yet often misunderstood heart conditions. Physicians have a crucial role in recognizing, diagnosing, and managing AFib to prevent its potentially life-threatening complications.
Bernard's Heart & Vascular Center , Jonesboro, Arkansas) mark a significant milestone in the pursuit of innovative solutions for non-valvular atrial fibrillation (NVAF) treatment. Patients with NVAF deemed appropriate for LAAX to reduce the risk of stroke and systemic embolism, will participate in this research effort.
The results support the use of workflows to reduce radiation exposure during catheter ablation for the treatment of paroxysmal atrial fibrillation (AFib) while maintaining safety, efficacy, and long-term patient outcomes comparable to traditional procedures.1 Circulation Research. Int J Stroke. 2021 Feb;16(2):217-221.
A local startup is introducing an innovative AI targeting this growing danger. The AI lineup currently covers both continuous ECG tracking and AFib detection. You are currently developing a new AI to detect AFib. Can you share the details of your study findings after testing your AFib AI detection model?
OSA is commonly seen in patients with arrhythmias like atrial fibrillation (AFib) and due to the variable unpredictable nature of sleep apnea symptoms, it is often untreated, leading to adverse outcomes. Peerbridge Health continues to innovate by compounding clinical utility in one simple device," said Andrea Natale, M.D.,
11, 2025, at HonorHealth Research Institute, Rahul Doshi, M.D., Using the same catheter, he also was able to easily switch to radiofrequency ablation, which has traditionally been used to treat Afib by scarring the damaged part of the heart using heat. Learn more at HonorHealth.com/research. 12, 2025 On Feb. of the adult U.S.
Based on the results from the admIRE clinical trial, we are confident that this innovation has the promise to deliver significant value and differentiated capabilities, and become an important tool for the treatment of AFib." 2,3 Approximately 1 in 4 adults over the age of 40 are at risk for developing AFib. In the U.S.,
Image courtesy: Getty Images christine.book Sat, 05/18/2024 - 14:26 May 18, 2024 — The Heart Rhythm Society ( HRS ) has announced the findings of three new studies demonstrating the safety and efficacy of pulsed field ablation (PFA), a nonthermal ablation treatment for patients with atrial fibrillation ( AFib ).
Boston Scientific made what could become a major addition to its electrophysiology portfolio, acquiring AFib mapping startup Cortex, Inc. Cortex gives Boston Scientific a new mapping technology that detects AFib signs and triggers outside of the pulmonary veins, and can help EP teams develop ablation strategies for more complex AFib cases.
As the AHA celebrates its 100th year, the conference reflected on a century of innovation while exploring the future of cardiovascular disease prevention and management. OPTION Trial : LAAC after AFib ablation was associated with lower risks of major bleeding compared to oral anticoagulation. Access the full study. View the study.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content